Treatment of Chronic Obstructive Pulmonary Disease (Copd) and Anti-Inflammatory Diseases

Technology #ua15-181

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Kwang Chul Kim
Professor, Otolaryngology
Managed By
Rakhi Gibbons
Asst. Director, Life Sciences (520) 626-6695

Title: Treatment of Toll-Like Receptor-Mediated Inflammation

Invention: This invention is a chronic obstructive pulmonary disease (COPD) treatment that inhibits signaling of Toll-Like Receptors which cause inflammation in the lungs. The drug mimics the action of an anti-inflammatory glycoprotein by recreating a peptide sequence in the protein and directing it into the affected cells. The drug can then have the anti-inflammatory effect of the protein without the cytotoxic effects.

Background: MUC1 is a glycoprotein with anti-inflammatory activity in mucosal epithelial cells, with the anti-inflammatory effect resulting from a particular peptide sequence within the protein. That peptide sequence, along with two carrier molecules, was found by the inventors to have anti-inflammatory effects in mice with COPD-like inflammation.


  • Commercial; pharmaceutical
  • Research; pharmaceutical


  • Treats early stages of pulmonary inflammation before chronic inflammation can develop instead of treating incurable chronic inflammation
  • Small molecule with highly specific activity
  • Mimics the function of a naturally occurring protein
  • Does not have the cytotoxic effects associated with increased concentration of the natural protein¬†